



Bismuth Subsalicylate BP 17.5 mg/ml

Oral Suspension

Composition

Pink-Bismol Oral Suspension: Each 5 ml oral suspension contains 87.5mg Bismuth Subsalicylate BP.

Pharmacology

Antacid action: **Pink-Bismol** (Bismuth Subsalicylate BP) coats ulcer surface, protecting it from acid and pepsin. It stimulates mucus and bicarbonate secretion and also reacts with HCl, produces bismuth oxychloride and salicylic acid thus reduces HCl.

Anti-diarrheal action: It stimulates absorption of water and electrolytes across the intestinal wall. In infectious diarrhea, it binds with toxin produced by *E.coli*, disrupts cell, causing lysis of *H.pylori* and prevents adhesion of *H.pylori* in the cell wall of intestine.

Anti-inflammatory action: When hydrolyzed to salicylic acid, it inhibits prostaglandin G/H synthase $\frac{1}{2}$. Thus reduces inflammation and coats the irritated tissue to retard the expulsion of fluid.

Indications

Bismuth Subsalicylate is indicated for upset stomach, indigestion, heartburn, nausea and diarrhea.

Dosage and administration

Adult (>16)	30 ml in dosing cup provided or 6 x 5 ml spoonful
Children : (10-14 years)	15 ml (3 teaspoons)
(5-9 years)	7.5 ml (1 $\frac{1}{2}$ teaspoons)
(3-4 years)	5 ml (1 teaspoon)

- ◆ Children under 3 years : Ask a doctor.
- ◆ Repeat dose every $\frac{1}{2}$ to 1 hour if needed. Not more than 8 doses to be taken in 24 hours.

Precautions

Do not take with aspirin or other salicylates. Caution should be exercised by patients taking medicines for anti-coagulation (thinning of the blood), diabetes or gout.

Contraindications

Bismuth Subsalicylate should not be used by patients hypersensitive to Aspirin or other salicylates or any ingredient in this formulation.

Keep all medicines out of reach and sight of children.

Side effects

Black stool and black tongue is common with use of Bismuth Subsalicylate.

Bismuth Subsalicylate should not be used if symptoms are severe or persist for more than 2 days.

Do not exceed the recommended dose, shake bottle before use.

For oral use only

Pregnancy and Lactation

There are no adequate data concerning the use of Bismuth Subsalicylate in pregnant women.

Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition and postnatal development. The potential risk for human is unknown.

Bismuth Subsalicylate should not be used during lactation unless clearly necessary.

Use in elderly

No special precaution is needed. But patient is suffering from renal insufficiency, caution should be taken.

Overdose

Bismuth intoxication may present as an acute encephalopathy with confusion, myoclonic movements, tremor, dysarthria and walking and standing disorders. Bismuth intoxication may also cause gastrointestinal disturbances, skin reactions, discoloration of mucous membranes, and renal dysfunction as a result of acute tubular necrosis. Treatment includes gastric lavage, purgation and hydration. Chelating agents may be effective in the early stages following ingestion and haemodialysis may be necessary.

Overdose of Bismuth Subsalicylate may also give symptoms of salicylate intoxicification e.g. dizziness, tinnitus, sweating, nausea, headache.

If symptoms occur, use of Bismuth Subsalicylate should be discontinued. Management of overdose is the same as that for salicylate overdose.

Storage

Store in a cool and dry place (25°C).

Packaging

Each pack contains 200 ml Bismuth Subsalicylate oral suspension with a 30 ml measuring cup.

Manufactured by



Ziska Pharmaceuticals Ltd.

Kaliakoir, Gazipur, Bangladesh